NCT06008028

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy Volunteers

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 4-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1015" and co-administration of "BR1015-1" and "BR1015-2" under fasting conditions in healthy volunteers

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	BR1015	One tablet administered alone
DRUG	BR1015-1	One tablet administered alone
DRUG	BR1015-2	One tablet administered alone

Timeline

• Start date: 2023-08-10
• Primary completion: 2023-10-06
• Completion: 2023-10-06
• First posted: 2023-08-23
• Last updated: 2023-11-18

Locations

1 site across 1 country: South Korea